Drugs / FRUNEXIAN
FRUNEXIAN
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02914353 | Jul 2016 → May 2017 | osteoarthritis, knee | eXIthera Pharmaceuticals | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05040776 | Oct 2023 → May 2024 | COVID-19, thrombocytopenia | eXIthera Pharmaceuticals | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FRUNEXIAN | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314583 ↗ |
| Known as | EP-7041 | “This First-In-Human study will evaluate the safety and tolerability, pharmacokinetic profile, and pharmacodynamic effects of EP-7041, a novel Factor XIa inhibitor, following IV...” NCT02914353 ↗ |
| Known as | EP-7041 HCl | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314583 ↗ |
| Known as | FRUNEXIAN HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314583 ↗ |
| Action | Inhibit | “a novel Factor XIa inhibitor” NCT02914353 ↗ |
| Modality | Small molecule | — CHEMBL5314583 ↗ |
| Route | Intravenous | “following IV administration” NCT02914353 ↗ |